Background Chronic lymphocytic leukemia (CLL) is the most common leukemia in adults. These malignant B-CLL cells represent over 99% of peripheral blood mononuclear cells (PBMCs) in CLL patients. In case of an aggressive form, the cell number may quickly double and, as a result, the disease may be fatal within a relatively short period of time .Currently several biomarkers are being used as CLL prognosticators, including: elevated protein levels (e.g. TCL-1, ZAP-70, CD38), elevated RNA levels (e.g. CLLU1, LPL, miRNAs), gene mutations (e.g.TP53, SF3B1, BIRC3, NOTCH1) and epigenetic changes. Early reports implicated IL-6 as pro-tumorigenic factor in various human tumors. IL-6 levels increased significantly in serum of CLL patients and correlated with adverse clinical features and short survival. Aim of the work Is to evaluate IL 6 level in patients with CLL at time of presentation and 6 months after chemotherapy and to study its relevance to disease prognosis. Patients and Methods This Study is a cross sectional study that was conducted on 55 patients newly diagnosed with chronic lymphocytic leukemia (CLL) in Clinical Hematology Unit in Ain-Shams University Hospitals in Cairo, Egypt. The control group included 50 healthy control subjects. Result The initial serum IL 6 level in the patient group (pre-treatment) ranged from 36-91pg/mL (median 57), and in the control group it ranged from 1-2 pg/mL (median 1).The initial serum IL 6 level in patient group (pre-treatment) range from 36-91 pg/mL (median 57), and in patient group (post treatment) range from 1-32 pg/mL (median 2).There are positive correlations between IL6 level and with WBC, B2 microglobulin, LDH, ESR, B symptoms, Uric Acid, BM Aspirate (% of lymphocytes)and Binet and Rai staging system. Conclusion Serum IL 6 is a useful poor prognostic marker in newly diagnosed CLL patients, its prognostic value goes with the other known prognostic markers as the lymphocytic count, ESR and LDH. Abbreviations: CLL (chronic lymphocytic leukaemia); IL-6 (interleukin 6).
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2025 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.